Skip to main content

Advertisement

SpringerLink
Log in

Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Induction of tumor-antigen-specific T cells in active cancer immunotherapy is generally difficult due to the very low anti-tumoral precursor cytotoxic T cells. By improving tumor-antigen uptake and presentation by dendritic cells (DCs), this problem can be overcome. Focusing on MAGE-A3 protein, frequently expressed in many types of tumors, we analyzed different DC-uptake routes after additional coating the recombinant MAGE-A3 protein with either a specific monoclonal antibody or an immune complex formulation. Opsonization of the protein with antibody resulted in increased DC-uptake compared to the uncoated rhMAGE-A3 protein. This was partly due to Fcγ receptor-dependent internalization. However, unspecific antigen internalization via macropinocytosis also played a role. When analyzing DC-uptake of MAGE-A3 antigen expressed in multiple myeloma cell line U266, pretreatment with proteasome inhibitor bortezomib resulted in increased apoptosis compared to γ-irradiation. Bortezomib-mediated immunogenic apoptosis, characterized by elevated surface expression of hsp90, triggered higher phagocytosis of U266 cells by DCs involving specific DC-derived receptors. We further investigated the impact of antigen delivery on T-cell priming. Induction of CD8+ T-cell response was favored by stimulating naïve T cells with either antibody-opsonized MAGE-A3 protein or with the bortezomib-pretreated U266 cells, indicating that receptor-mediated uptake favors cross-presentation of antigens. In contrast, CD4+ T cells were preferentially induced after stimulation with the uncoated protein or protein in the immune complex, both antigen formulations were preferentially internalized by DCs via macropinocytosis. In summary, receptor-mediated DC-uptake mechanisms favored the induction of CD8+ T cells, relevant for clinical anti-tumor response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Van den Eynde BJ, van der Bruggen P (1997) T cell defined tumor antigens. Curr Opin Immunol 9:684–693

    Article  PubMed  Google Scholar 

  2. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K et al (2009) Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 15:1343–1352

    Article  PubMed  CAS  Google Scholar 

  3. Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y et al (2007) MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res 67:9954–9962

    Article  PubMed  CAS  Google Scholar 

  4. Laduron S, Deplus R, Zhou S, Kholmanskikh O, Godelaine D et al (2004) MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res 32:4340–4350

    Article  PubMed  CAS  Google Scholar 

  5. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S et al (2006) MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA 103:11160–11165

    Article  PubMed  CAS  Google Scholar 

  6. Marcar L, Maclaine NJ, Hupp TR, Meek DW (2010) Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res 70:10362–10370

    Article  PubMed  CAS  Google Scholar 

  7. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA et al (2008) Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA 105:1650–1655

    Article  PubMed  CAS  Google Scholar 

  8. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P (1998) Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer 77:538–542

    Article  PubMed  CAS  Google Scholar 

  9. Brichard VG, Lejeune D (2007) GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine 25(Suppl 2):B61–B71

    Article  PubMed  CAS  Google Scholar 

  10. Schnurr M, Chen Q, Shin A, Chen W, Toy T et al (2005) Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery. Blood 105:2465–2472

    Article  PubMed  CAS  Google Scholar 

  11. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation of Cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125–133

    Article  PubMed  CAS  Google Scholar 

  12. Jeannin P, Jaillon S, Delneste Y (2008) Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 20:530–537

    Article  PubMed  CAS  Google Scholar 

  13. Spisek R, Charalambous A, Mazumder A, Vesole DH, Jagannath S et al (2007) Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 109:4839–4845

    Article  PubMed  CAS  Google Scholar 

  14. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L et al (1997) Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 27:3135–3142

    Article  PubMed  CAS  Google Scholar 

  15. Thomas-Kaskel AK, Portugal TG, Herchenbach D, Houet LV, Finke HJ (2007) Allogeneic HLA-matched donor dendritic cells loaded with patient leukemic blasts preferentially induce CD4-positive leukemia-reactive donor lymphocytes. Acta Haematol pp 226–235

  16. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C et al (2002) Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 188:51–64

    Article  Google Scholar 

  17. Consogno G, Manici S, Facchinetti V, Bachi A, Hammer J et al (2003) Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. Blood 101:1038–1044

    Article  PubMed  CAS  Google Scholar 

  18. Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F et al (2007) Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood 109:1103–1112

    Article  PubMed  CAS  Google Scholar 

  19. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F et al (2007) Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother 30:847–854

    Article  PubMed  Google Scholar 

  20. Lambert SL, Okada CY, Levy R (2004) TCR vaccines against a murine T cell lymphoma: a primary role for antibodies of the IgG2c class in tumor protection. J Immunol 172:929–936

    PubMed  CAS  Google Scholar 

  21. Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47

    Article  PubMed  CAS  Google Scholar 

  22. Iida S, Kuni-Kamochi RMK, Misaka H, Inoue M et al (2009) Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer 9:58

    Article  PubMed  Google Scholar 

  23. Bevaart L, Jansen MJ, van Vugt MJ, Verbeek JS, van de Winkel JG et al (2006) The high-affinity IgG receptor, FcgammaRI, plays a central role in antibody therapy of experimental melanoma. Cancer Res 66:1261–1264

    Article  PubMed  CAS  Google Scholar 

  24. Basu S, Binder RJ, Ramalingam T, Srivastava PK (2001) CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14:303–313

    Article  PubMed  CAS  Google Scholar 

  25. Liu B, Dai J, Zheng H, Stoilova D, Sun S et al (2003) Cell surface expression of an endoplasmic reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases. Proc Natl Acad Sci USA 100:15824–15829

    Article  PubMed  CAS  Google Scholar 

  26. Dai J, Liu B, Caudill MM, Zheng H, Qiao Y et al (2003) Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun 3:1

    PubMed  Google Scholar 

  27. di Pietro A, Tosti G, Ferrucci PF, Testori A (2009) Heat shock protein peptide complex 96-based vaccines in melanoma: How far we are, how far we can get. Hum Vaccin 5:727–737

    Article  Google Scholar 

Download references

Acknowledgments

We thank GlaxoSmithKline Vaccines, Rixensart, Belgium, for providing human recombinant MAGE-A3 protein. We thank Dr. Marie Follo for expert technical support with the Scan^R imaging system. This work was supported by a grant from the Deutsche Krebshilfe.

Conflict of interest

The authors declare no potential conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology/Oncology, University Medical Center Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany

    Ines Moeller, Jürgen Finke, Hendrik Veelken & Leonora Houet

  2. Faculty of Biology, University of Freiburg, Schänzlestraße 1, 79104, Freiburg, Germany

    Ines Moeller

  3. Department of Biomedicine, University Hospital Basel, Hebelstrasse 20, 4031, Basel, Switzerland

    Giulio C. Spagnoli

Authors
  1. Ines Moeller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giulio C. Spagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hendrik Veelken
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leonora Houet
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Leonora Houet.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moeller, I., Spagnoli, G.C., Finke, J. et al. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes. Cancer Immunol Immunother 61, 2079–2090 (2012). https://doi.org/10.1007/s00262-012-1272-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-012-1272-y

Keywords

Search

Navigation